Last updated: 2026-09-16 11:44:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Zevra Therapeutics, Inc. (ZVRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11.73, with a market capitalisation of $715.57M and a P/E ratio of 11.95. Over the past 52 weeks, its price has ranged from $7.16 to $15.04. This page covers its latest market performance, valuation, price trends and company information.
$715.57M | |
$11.83 | |
$15.04 | |
$3.89 | |
$11.65 | |
150.00 | |
1.25M | |
11.95 | |
$15.04 | |
$7.16 | |
-- | |
-- |
Zevra Therapeutics, Inc. (ZVRA) is trading at $11.73 in pre-market trading as of 2026-09-16 11:14:00, up 0.70% ($0.08) from the previous close of $11.65
Pre-market trading shows how investors are pricing ZVRA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Zevra Therapeutics, Inc. (ZVRA) moved from $12.40 to $11.73, representing a decline of 5.40% ($0.67).
The stock traded between $11.52 and $12.90 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 841.49 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 58.0%
ZVRA is currently trading at $11.73, placing it 58.0% of the way from its 52-week low of $7.16 to its 52-week high of $15.04. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 61 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zevra Therapeutics, Inc. (ZVRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.